Plasma sICAM-1 correlates with tumor volume before primary radiochemotherapy of head and neck squamous cell carcinoma patients

1Bose P, Brockton NT, Dort JC. Head and neck cancer: from anatomy to biology. Int J Cancer 2013; 133: 2013-23. doi: 10.1002/ijc.28112 Bose P Brockton NT Dort JC Head and neck cancer: from anatomy to biology Int J Cancer 2013 133 2013 23 10.1002/ijc.2811223417723Open DOISearch in Google Scholar

2Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 2017; 67: 93-9. doi: 10.3322/caac.21388 Amin MB Greene FL Edge SB Compton CC Gershenwald JE Brookland RK et al The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging CA Cancer J Clin 2017 67 93 9 10.3322/caac.2138828094848Open DOISearch in Google Scholar

3Cramer JD, Hicks KE, Rademaker AW, Patel UA, Samant S. Validation of the eighth edition American Joint Committee on Cancer staging system for human papillomavirus-associated oropharyngeal cancer. Head Neck 2018; 40: 457-66. doi: 10.1002/hed.24974 Cramer JD Hicks KE Rademaker AW Patel UA Samant S Validation of the eighth edition American Joint Committee on Cancer staging system for human papillomavirus-associated oropharyngeal cancer Head Neck 2018 40 457 66 10.1002/hed.2497428990257Open DOISearch in Google Scholar

4Nevens D, Nuyts S. HPV-positive head and neck tumours, a distinct clinical entity. B-ENT 2015; 11: 81-7. PMID: 26563006 Nevens D Nuyts S HPV-positive head and neck tumours, a distinct clinical entity B-ENT 2015 11 81 7 PMID: 26563006Search in Google Scholar

5Rosenberg AJ, Vokes EE. Optimizing treatment de-escalation in head and neck cancer: current and future perspectives. Oncologist 2021; 26: 40-48. doi: 10.1634/theoncologist.2020-0303 Rosenberg AJ Vokes EE Optimizing treatment de-escalation in head and neck cancer: current and future perspectives Oncologist 2021 26 40 48 10.1634/theoncologist.2020-0303779417932864799Open DOISearch in Google Scholar

6Nonaka T, Wong DTW. Liquid biopsy in head and neck cancer: promises and challenges. J Dent Res 2018; 97: 701-8. doi: 10.1177/0022034518762071 Nonaka T Wong DTW Liquid biopsy in head and neck cancer: promises and challenges J Dent Res 2018 97 701 8 10.1177/0022034518762071596088229513618Open DOISearch in Google Scholar

7Arantes L, De Carvalho AC, Melendez ME, Lopes Carvalho A. Serum, plasma and saliva biomarkers for head and neck cancer. Expert Rev Mol Diagn 2018; 18: 85-112. doi: 10.1080/14737159.2017.1404906 Arantes L De Carvalho AC Melendez ME Lopes Carvalho A Serum, plasma and saliva biomarkers for head and neck cancer Expert Rev Mol Diagn 2018 18 85 112 10.1080/14737159.2017.140490629134827Open DOISearch in Google Scholar

8Schaaij-Visser TB, Brakenhoff RH, Leemans CR, Heck AJ, Slijper M. Protein biomarker discovery for head and neck cancer. J Proteomics 2010; 73: 1790-803. doi: 10.1016/j.jprot.2010.01.013 Schaaij-Visser TB Brakenhoff RH Leemans CR Heck AJ Slijper M Protein biomarker discovery for head and neck cancer J Proteomics 2010 73 1790 803 10.1016/j.jprot.2010.01.01320139037Open DOISearch in Google Scholar

9Rostami A, Bratman SV. Utilizing circulating tumour DNA in radiation oncology. Radiother Oncol 2017; 124: 357-64. doi: 10.1016/j.radonc.2017.07.004 Rostami A Bratman SV Utilizing circulating tumour DNA in radiation oncology Radiother Oncol 2017 124 357 64 10.1016/j.radonc.2017.07.00428735685Open DOISearch in Google Scholar

10De Michino S, Aparnathi M, Rostami A, Lok BH, Bratman SV. The utility of liquid biopsies in radiation oncology. Int J Radiat Oncol Biol Phys 2020; 107: 873-86. doi: 10.1016/j.ijrobp.2020.05.008 De Michino S Aparnathi M Rostami A Lok BH Bratman SV The utility of liquid biopsies in radiation oncology Int J Radiat Oncol Biol Phys 2020 107 873 86 10.1016/j.ijrobp.2020.05.00832417410Open DOISearch in Google Scholar

11Kawaguchi K, Sakurai M, Yamamoto Y, Suzuki E, Tsuda M, Kataoka TR, et al. Alteration of specific cytokine expression patterns in patients with breast cancer. Sci Rep 2019; 9: 2924. doi: 10.1038/s41598-019-39476-9 Kawaguchi K Sakurai M Yamamoto Y Suzuki E Tsuda M Kataoka TR et al Alteration of specific cytokine expression patterns in patients with breast cancer Sci Rep 2019 9 2924 10.1038/s41598-019-39476-9639352430814616Open DOISearch in Google Scholar

12Chang KP, Chang YT, Wu CC, Liu YL, Chen MC, Tsang NM, et al. Multiplexed immunobead-based profiling of cytokine markers for detection of naso-pharyngeal carcinoma and prognosis of patient survival. Head Neck 2011; 33: 886-97. doi: 10.1002/hed.21557 Chang KP Chang YT Wu CC Liu YL Chen MC Tsang NM et al Multiplexed immunobead-based profiling of cytokine markers for detection of naso-pharyngeal carcinoma and prognosis of patient survival Head Neck 2011 33 886 97 10.1002/hed.2155721560180Open DOISearch in Google Scholar

13Mojtahedi Z, Khademi B, Yehya A, Talebi A, Fattahi MJ, Ghaderi A. Serum levels of interleukins 4 and 10 in head and neck squamous cell carcinoma. J Laryngol Otol 2012; 126: 175-9. doi: 10.1017/s0022215111002349 Mojtahedi Z Khademi B Yehya A Talebi A Fattahi MJ Ghaderi A Serum levels of interleukins 4 and 10 in head and neck squamous cell carcinoma J Laryngol Otol 2012 126 175 9 10.1017/s002221511100234921888745Open DOISearch in Google Scholar

14Chehrazi-Raffle A, Meza L, Alcantara M, Dizman N, Bergerot P, Salgia N, et al. Circulating cytokines associated with clinical response to systemic therapy in metastatic renal cell carcinoma. J Immunother Cancer 2021; 9. doi: 10.1136/jitc-2020-002009 Chehrazi-Raffle A Meza L Alcantara M Dizman N Bergerot P Salgia N et al Circulating cytokines associated with clinical response to systemic therapy in metastatic renal cell carcinoma J Immunother Cancer 2021 9 10.1136/jitc-2020-002009794497133688021Open DOISearch in Google Scholar

15Nikolinakos PG, Altorki N, Yankelevitz D, Tran HT, Yan S, Rajagopalan D. et al. Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib. Cancer Res 2010; 70: 2171-9. doi: 10.1158/0008-5472.Can-09-2533 Nikolinakos PG Altorki N Yankelevitz D Tran HT Yan S Rajagopalan D. et al Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib Cancer Res 2010 70 2171 9 10.1158/0008-5472.Can-09-2533Open DOISearch in Google Scholar

16Jin YB, Zhang GY, Lin KR, Chen XP, Cui JH, Wang YJ, et al. Changes of plasma cytokines and chemokines expression level in nasopharyngeal carcinoma patients after treatment with definitive intensity-modulated radiotherapy (IMRT). PLoS One 2017; 12: e0172264. doi: 10.1371/journal.pone.0172264 Jin YB Zhang GY Lin KR Chen XP Cui JH Wang YJ et al Changes of plasma cytokines and chemokines expression level in nasopharyngeal carcinoma patients after treatment with definitive intensity-modulated radiotherapy (IMRT) PLoS One 2017 12 e0172264 10.1371/journal.pone.0172264531286728207826Open DOISearch in Google Scholar

17Snitcovsky I, Leitão GM, Pasini FS, Brunialti KC, Mangone FR, Maistro S, et al. Plasma osteopontin levels in patients with head and neck cancer undergoing chemoradiotherapy. Arch Otolaryngol Head Neck Surg 2009; 135: 807-11. doi: 10.1001/archoto.2009.103 Snitcovsky I Leitão GM Pasini FS Brunialti KC Mangone FR Maistro S et al Plasma osteopontin levels in patients with head and neck cancer undergoing chemoradiotherapy Arch Otolaryngol Head Neck Surg 2009 135 807 11 10.1001/archoto.2009.10319687403Open DOISearch in Google Scholar

18Lavaee F, Zare S, Mojtahedi Z, Malekzadeh M, Khademi B, Ghaderi A. Serum CXCL12, but not CXCR4, is associated with head and neck squamous cell carcinomas. Asian Pac J Cancer Prev 2018; 19: 901-4. doi: 10.22034/apjcp.2018.19.4.901 Lavaee F Zare S Mojtahedi Z Malekzadeh M Khademi B Ghaderi A Serum CXCL12, but not CXCR4, is associated with head and neck squamous cell carcinomas Asian Pac J Cancer Prev 2018 19 901 4 10.22034/apjcp.2018.19.4.901Open DOISearch in Google Scholar

19Feltl D, Zavadova E, Pala M, Hozak P. The dynamics of plasma transforming growth factor beta 1 (TGF-beta1) level during radiotherapy with or without simultaneous chemotherapy in advanced head and neck cancer. Oral Oncol 2005; 41: 208-13. doi: 10.1016/j.oraloncology.2004.09.005 Feltl D Zavadova E Pala M Hozak P The dynamics of plasma transforming growth factor beta 1 (TGF-beta1) level during radiotherapy with or without simultaneous chemotherapy in advanced head and neck cancer Oral Oncol 2005 41 208 13 10.1016/j.oraloncology.2004.09.00515695123Open DOISearch in Google Scholar

20Andersson B, Lewin F, Lundgren J, Nilsson M, Rutqvist LE, Löfgren S, et al. Plasma tumor necrosis factor-α and C-reactive protein as biomarker for survival in head and neck squamous cell carcinoma. J Cancer Res Clin Oncol 2014; 140: 515-9. doi: 10.1007/s00432-014-1592-8 Andersson B Lewin F Lundgren J Nilsson M Rutqvist LE Löfgren S et al Plasma tumor necrosis factor-α and C-reactive protein as biomarker for survival in head and neck squamous cell carcinoma J Cancer Res Clin Oncol 2014 140 515 9 10.1007/s00432-014-1592-824481866Open DOISearch in Google Scholar

21Clasen K, Welz S, Faltin H, Zips D, Eckert F. Dynamics of HMBG1 (High Mobility Group Box 1) during radiochemotherapy correlate with outcome of HNSCC patients. Strahlenther Onkol 2021; 98: 194-200. doi: 10.1007/s00066-021-01860-8 Clasen K Welz S Faltin H Zips D Eckert F Dynamics of HMBG1 (High Mobility Group Box 1) during radiochemotherapy correlate with outcome of HNSCC patients Strahlenther Onkol 2021 98 194 200 10.1007/s00066-021-01860-8878963034671818Open DOISearch in Google Scholar

22Shimizu Y, Minemura M, Tsukishiro T, Kashii Y, Miyamoto M, Nishimori H, et al. Serum concentration of intercellular adhesion molecule-1 in patients with hepatocellular carcinoma is a marker of the disease progression and prognosis. Hepatology 1995; 22: 525-31. PMID: 7543436 Shimizu Y Minemura M Tsukishiro T Kashii Y Miyamoto M Nishimori H et al Serum concentration of intercellular adhesion molecule-1 in patients with hepatocellular carcinoma is a marker of the disease progression and prognosis Hepatology 1995 22 525 31 PMID: 754343610.1002/hep.1840220223Search in Google Scholar

23Araki T, Miki C, Kusunoki M. Biological implications of circulating soluble intercellular adhesion molecule-1 in colorectal cancer patients. Scand J Gastroenterol 2001; 36: 399-404. doi: 10.1080/003655201300051234 Araki T Miki C Kusunoki M Biological implications of circulating soluble intercellular adhesion molecule-1 in colorectal cancer patients Scand J Gastroenterol 2001 36 399 404 10.1080/00365520130005123411336165Open DOISearch in Google Scholar

24Long EO. ICAM-1: getting a grip on leukocyte adhesion. J Immunol 2011; 186: 5021-3. doi: 10.4049/jimmunol.1100646 Long EO ICAM-1: getting a grip on leukocyte adhesion J Immunol 2011 186 5021 3 10.4049/jimmunol.1100646386074421505213Open DOISearch in Google Scholar

25Witkowska AM, Borawska MH. Soluble intercellular adhesion molecule-1 (sICAM-1): an overview. Eur Cytokine Netw 2004; 15: 91-8. PMID: 15319166 Witkowska AM Borawska MH Soluble intercellular adhesion molecule-1 (sICAM-1): an overview Eur Cytokine Netw 2004 15 91 8 PMID: 15319166Search in Google Scholar

26Maruo Y, Gochi A, Kaihara A, Shimamura H, Yamada T, Tanaka N, et al. ICAM-1 expression and the soluble ICAM-1 level for evaluating the metastatic potential of gastric cancer. Int J Cancer 2002; 100: 486-90. doi: 10.1002/ijc.10514 Maruo Y Gochi A Kaihara A Shimamura H Yamada T Tanaka N et al ICAM-1 expression and the soluble ICAM-1 level for evaluating the metastatic potential of gastric cancer Int J Cancer 2002 100 486 90 10.1002/ijc.1051412115535Open DOISearch in Google Scholar

27Yoo NC, Chung HC, Chung HC, Park JO, Rha SY, Kim JH, et al. Synchronous elevation of soluble intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) correlates with gastric cancer progression. Yonsei Med J 1998; 39: 27-36. doi: 10.3349/ymj.1998.39.1.27 Yoo NC Chung HC Chung HC Park JO Rha SY Kim JH et al Synchronous elevation of soluble intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) correlates with gastric cancer progression Yonsei Med J 1998 39 27 36 10.3349/ymj.1998.39.1.279529982Open DOISearch in Google Scholar

28Okamoto Y, Tsurunaga T, Ueki M. Serum soluble ICAM-1 levels in the patients with cervical cancer. Acta Obstet Gynecol Scand 1999; 78: 60-5. PMID: 9926894 Okamoto Y Tsurunaga T Ueki M Serum soluble ICAM-1 levels in the patients with cervical cancer Acta Obstet Gynecol Scand 1999 78 60 5 PMID: 992689410.1080/j.1600-0412.1999.780113.xSearch in Google Scholar

29Basoglu M, Atamanalp SS, Yildirgan MI, Aydinli B, Ozturk G, Akcay F, et al. Correlation between the serum values of soluble intercellular adhesion molecule-1 and total sialic acid levels in patients with breast cancer. Eur Surg Res 2007; 39: 136-40. doi: 10.1159/000100110 Basoglu M Atamanalp SS Yildirgan MI Aydinli B Ozturk G Akcay F et al Correlation between the serum values of soluble intercellular adhesion molecule-1 and total sialic acid levels in patients with breast cancer Eur Surg Res 2007 39 136 40 10.1159/00010011017337890Open DOISearch in Google Scholar

30Köstler WJ, Tomek S, Brodowicz T, Budinsky AC, Flamm M, Hejna M, et al. Soluble ICAM-1 in breast cancer: clinical significance and biological implications. Cancer Immunol Immunother 2001; 50: 483-90. doi: 10.1007/s002620100223 Köstler WJ Tomek S Brodowicz T Budinsky AC Flamm M Hejna M et al Soluble ICAM-1 in breast cancer: clinical significance and biological implications Cancer Immunol Immunother 2001 50 483 90 10.1007/s00262010022311761443Open DOISearch in Google Scholar

31Levin I, Klein T, Shapira Y, Lurie H, Kfir B, Narinsky R, et al. Serum intracellular adhesion molecule-1 (sicam-1) and soluble hla class-1 antigens in breast-cancer patients in relation to tumor burden. Oncol Rep 1994; 1: 217-20. doi: 10.3892/or.1.1.217 Levin I Klein T Shapira Y Lurie H Kfir B Narinsky R et al Serum intracellular adhesion molecule-1 (sicam-1) and soluble hla class-1 antigens in breast-cancer patients in relation to tumor burden Oncol Rep 1994 1 217 20 10.3892/or.1.1.21721607340Open DOISearch in Google Scholar

32Dymicka-Piekarska V, Guzinska-Ustymowicz K, Kuklinski A, Kemona H. Prognostic significance of adhesion molecules (sICAM-1, sVCAM-1) and VEGF in colorectal cancer patients. Thromb Res 2012; 129: e47-50. doi: 10.1016/j.thromres.2011.12.004 Dymicka-Piekarska V Guzinska-Ustymowicz K Kuklinski A Kemona H Prognostic significance of adhesion molecules (sICAM-1, sVCAM-1) and VEGF in colorectal cancer patients Thromb Res 2012 129 e47 50 10.1016/j.thromres.2011.12.00422209338Open DOISearch in Google Scholar

33Schellerer VS, Langheinrich MC, Zver V, Grützmann R, Stürzl M, Gefeller O, et al. Soluble intercellular adhesion molecule-1 is a prognostic marker in colorectal carcinoma. Int J Colorectal Dis 2019; 34: 309-17. doi: 10.1007/s00384-018-3198-0 Schellerer VS Langheinrich MC Zver V Grützmann R Stürzl M Gefeller O et al Soluble intercellular adhesion molecule-1 is a prognostic marker in colorectal carcinoma Int J Colorectal Dis 2019 34 309 17 10.1007/s00384-018-3198-0633174130470940Open DOISearch in Google Scholar

34Toiyama Y, Miki C, Inoue Y, Okugawa Y, Koike Y, Yokoe T, et al. Soluble intercellular adhesion molecule-1 as a prognostic marker for stage II colorectal cancer patients. Ann Surg Oncol 2008; 15: 1617-24. doi: 10.1245/s10434-008-9874-5 Toiyama Y Miki C Inoue Y Okugawa Y Koike Y Yokoe T et al Soluble intercellular adhesion molecule-1 as a prognostic marker for stage II colorectal cancer patients Ann Surg Oncol 2008 15 1617 24 10.1245/s10434-008-9874-518368454Open DOISearch in Google Scholar

35Gu X, Ma C, Yuan D, Song Y. Circulating soluble intercellular adhesion molecule-1 in lung cancer: a systematic review. Transl Lung Cancer Res 2012; 1: 36-44. doi: 10.3978/j.issn.2218-6751.08.01 Gu X Ma C Yuan D Song Y Circulating soluble intercellular adhesion molecule-1 in lung cancer: a systematic review Transl Lung Cancer Res 2012 1 36 44 10.3978/j.issn.2218-6751.08.01436758125806153Open DOISearch in Google Scholar

36Wu M, Tong X, Wang D, Wang L, Fan H. Soluble intercellular cell adhesion molecule-1 in lung cancer: A meta-analysis. Pathol Res Pract 2020; 216: 153029. doi: 10.1016/j.prp.2020.153029 Wu M Tong X Wang D Wang L Fan H Soluble intercellular cell adhesion molecule-1 in lung cancer: A meta-analysis Pathol Res Pract 2020 216 153029 10.1016/j.prp.2020.15302932853940Open DOISearch in Google Scholar

37Kawano T, Yanoma S, Nakamura Y, Shiono O, Kokatu T, Kubota A, et al. Evaluation of soluble adhesion molecules CD44 (CD44st, CD44v5, CD44v6), ICAM-1, and VCAM-1 as tumor markers in head and neck cancer. Am J Otolaryngol 2005; 26: 308-13. doi: 10.1016/j.amjoto.2005.02.005 Kawano T Yanoma S Nakamura Y Shiono O Kokatu T Kubota A et al Evaluation of soluble adhesion molecules CD44 (CD44st, CD44v5, CD44v6), ICAM-1, and VCAM-1 as tumor markers in head and neck cancer Am J Otolaryngol 2005 26 308 13 10.1016/j.amjoto.2005.02.00516137528Open DOISearch in Google Scholar

38Kubala MH, DeClerck YA. The plasminogen activator inhibitor-1 paradox in cancer: a mechanistic understanding. Cancer Metastasis Rev 2019; 38: 48392. doi: 10.1007/s10555-019-09806-4 Kubala MH DeClerck YA The plasminogen activator inhibitor-1 paradox in cancer: a mechanistic understanding Cancer Metastasis Rev 2019 38 48392 10.1007/s10555-019-09806-4700178031734763Open DOISearch in Google Scholar

39Zwirner K, Hilke FJ, Demidov G, Ossowski S, Gani C, Rieß O, et al. Circulating cell-free DNA: A potential biomarker to differentiate inflammation and infection during radiochemotherapy. Radiother Oncol 2018; 129: 575-81. doi: 10.1016/j.radonc.2018.07.016 Zwirner K Hilke FJ Demidov G Ossowski S Gani C Rieß O et al Circulating cell-free DNA: A potential biomarker to differentiate inflammation and infection during radiochemotherapy Radiother Oncol 2018 129 575 81 10.1016/j.radonc.2018.07.01630097252Open DOISearch in Google Scholar